55513-0132 Kanjinti - CanMED: NDC

Product NDC:

55513-0132

Brand Name:

Kanjinti

Generic Name:

trastuzumab-anns

Dosage Form Name:

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Administration Route:

Intravenous

Substances:

Name: TRASTUZUMAB

Strength: 420.0

Unit: mg/20mL

Packages:

Code: 55513-0132-01

Description: 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01) / 20 mL in 1 VIAL, MULTI-DOSE

Effective Date: June 11, 2019

Discontinued:

Code: 55513-0132-21

Description: 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-21) / 20 mL in 1 VIAL, MULTI-DOSE

Effective Date: July 1, 2025

Discontinued:

SEER*Rx Category:

Immunotherapy

Major Class:

Monoclonal Antibody

Minor Class:

HER2

Orphan Drug Designation:

Status:

In Use

CanMED and the Oncology Toolbox